ZVRA Key Statistics, Chart & Performance
The current stock price of ZVRA is 8.87 USD. In the past month the price increased by 3.14%. In the past year, price increased by 5.72%.
ZVRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.01 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 500.24B | ||
| MRK | MERCK & CO. INC. | 12.12 | 265.03B | ||
| PFE | PFIZER INC | 7.84 | 142.65B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.33 | 111.23B | ||
| ZTS | ZOETIS INC | 19.91 | 55.63B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 22.64B | ||
| VTRS | VIATRIS INC | 5.29 | 14.19B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.54 | 11.23B | ||
| CORT | CORCEPT THERAPEUTICS INC | 93.92 | 8.69B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About ZVRA
Company Profile
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 59 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Company Info
ZEVRA THERAPEUTICS INC
1180 Celebration Boulevard, Suite 103
Celebration FLORIDA US
Employees: 59
Phone: 13219393416
ZEVRA THERAPEUTICS INC / ZVRA FAQ
What does ZVRA do?
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 59 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
What is the stock price of ZEVRA THERAPEUTICS INC today?
The current stock price of ZVRA is 8.87 USD. The price increased by 2.66% in the last trading session.
Does ZVRA stock pay dividends?
ZVRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZVRA stock?
ZVRA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for ZEVRA THERAPEUTICS INC?
ZEVRA THERAPEUTICS INC (ZVRA) operates in the Health Care sector and the Pharmaceuticals industry.
Is ZEVRA THERAPEUTICS INC (ZVRA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZVRA.
Is ZEVRA THERAPEUTICS INC (ZVRA) expected to grow?
The Revenue of ZEVRA THERAPEUTICS INC (ZVRA) is expected to grow by 388.89% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ZVRA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ZVRA. When comparing the yearly performance of all stocks, ZVRA is a bad performer in the overall market: 65.7% of all stocks are doing better.
ZVRA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ZVRA. ZVRA may be in some trouble as it scores bad on both profitability and health.
ZVRA Financial Highlights
Over the last trailing twelve months ZVRA reported a non-GAAP Earnings per Share(EPS) of 0.45. The EPS increased by 122.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.86% | ||
| ROA | 13.08% | ||
| ROE | 26.53% | ||
| Debt/Equity | 0.46 |
ZVRA Forecast & Estimates
14 analysts have analysed ZVRA and the average price target is 23.31 USD. This implies a price increase of 162.84% is expected in the next year compared to the current price of 8.87.
For the next year, analysts expect an EPS growth of 157.77% and a revenue growth 388.89% for ZVRA